Skip to main content
SpringerLink
Log in

Future developments in treatment of atopic dermatitis

  • Chapter
Immunology and Drug Therapy of Allergic Skin Diseases

Part of the book series: Progress in Inflammation Research ((PIR))

  • 197 Accesses

Abstract

In recent years there have been major advances in both the understanding of basic mechanisms underlying atopic dermatitis and in the development of drugs with specific effects on different components of immune or inflammatory processes. These drugs form agents which can be used on the one hand to treat atopic dermatitis, and on the other, they represent tools which can help dissect the immuno-pharmacological mechanisms involved in the process. These agents will be studied over the next few years and some will come to form a new approach to the treatment of atopic dermatitis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Liu J (1993) FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunology Today 14 (6): 290–265

    Article  PubMed  CAS  Google Scholar 

  2. Rao A, Luo C, Hogan PG (1997) Transcription factors of the NFAT family: regulation and function. Ann Rev Immunol 15: 707–747

    Article  CAS  Google Scholar 

  3. Rao A (1995) NFATp, a cyclosporine-sensitive transcription factor implicated in cytokine gene induction. J Leukoc Biol 57: 536–542

    PubMed  CAS  Google Scholar 

  4. Munro CS, Higgins EM, Marks JM, Daly BM, Friedmann PS, Shuster S (1991) Cyclosporin A in atopic dermatitis: therapeutic response is dissociated from effects on allergic reactions. Br J Dermatol 124: 43–48

    Article  PubMed  CAS  Google Scholar 

  5. Camp RD, Reitamo S, Friedmann PS, Ho V, Heule F (1993) Cyclosporin A in severe, therapy-resistant atopic dermatitis: report of an international workshop, April 1993. Br J Dermatol 129: 217–220

    Article  PubMed  CAS  Google Scholar 

  6. Munro CS, Levell NJ, Shuster S, Friedmann PS (1994) Maintenance treatment with Cyclosporin in atopic eczema. Br J Dermatol 130: 376–80

    Article  PubMed  CAS  Google Scholar 

  7. Berth Jones J, Finlay AY, Zaki I, Tan BB, Goodyear H, Lewis-Jones MS, Cork MJ, Blee-hen SS, Salek MS, Allen BR et al (1996) Cyclosporine in severe childhood atopic-dermatitis - a multicenter study. J Am Acad Dermatol 34: 1016–1021

    Article  Google Scholar 

  8. Berth Jones J, Graham-Brown RAC, Marks B, Camp RDR, English JSC, Freeman K, Holden CA, Rogers SCF, Oliwiecki S, Friedmann PS et al (1997) Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol 136: 76–81

    Article  Google Scholar 

  9. Bieber T (1998) Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis. J Allergy Clin Immunol 102: 555–557

    Article  PubMed  CAS  Google Scholar 

  10. Nakagawa H, Etoh T, Ishibashi Y, Higaki Y, Kawashima M, Toni H, Harada S (1994) Tacrolimus ointment for atopic dermatitis. Lancet 344: 883

    Article  PubMed  CAS  Google Scholar 

  11. Aoyama H, Tabata N, Tanaka M, Uesugi Y, Tagami H (1995) Succesful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br J Dermatol 133: 494–495

    Article  PubMed  CAS  Google Scholar 

  12. Alaiti S, Kang SW, Fiedler VC, Ellis CN, Spurlin DV, Fader D, Ulyanov G, Gadgil SD,Tanase A, Lawrence I et al (1998) Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol 38: 69–76

    Article  PubMed  CAS  Google Scholar 

  13. Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DYM, Hanifin JM (1998) A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol 102: 637–44

    Article  PubMed  CAS  Google Scholar 

  14. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD, Jablonska S, Ahmed I, Thestruppedersen K, Daniel F et al (1997) A short-term trial of tacrolimus ointment for atopic dermatitis. New Engl J Med 337: 816–821

    Article  PubMed  CAS  Google Scholar 

  15. Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stutz A (1997) A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 137: 568–576

    Article  PubMed  CAS  Google Scholar 

  16. Rappersberger K, Meingassner JG, Fialla R, Fodinger D, Sterniczky B, Rauch S, Putz E, Stutz A, Wolff K (1996) Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol 106: 701–710

    Article  PubMed  CAS  Google Scholar 

  17. Hanifin JM, Chan SC, Cheng JB, Tofte SJ, Henderson WR, Kirby DS, Weiner ES (1996) Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 107: 51–56

    Article  PubMed  CAS  Google Scholar 

  18. Meingassner JG, Stutz A (1992) Antiinflammatory effects of macrophilin-interacting drugs in animal-models of irritant and allergic contact-dermatitis. Int Arch Allergy Immunol 99: 486–489

    Article  CAS  Google Scholar 

  19. Ransom JT (1995) Mechanism of action of mycophenolate mofetil. Therapeutic Drug Monitoring 17: 681–684

    Article  PubMed  CAS  Google Scholar 

  20. Goldblum R (1993) Therapy of rheumatoid-arthritis with mycophenolate mofetil. Clin Exp Rheumatol 11: S117–S119

    PubMed  Google Scholar 

  21. Nousari HC, Griffin WA, Anhalt GJ (1998) Successful therapy for bullous pemphigoid with mycophenolate mofetil. J Am Acad Dermatol 39: 497–498

    Article  PubMed  CAS  Google Scholar 

  22. Haufs MG, Beissert S, Grabbe S, Schutte B, Luger TA (1998) Psoriasis vulgaris treated successfully with mycophenolate mofetil. Br J Dermatol 138: 179–181

    Article  PubMed  CAS  Google Scholar 

  23. Hanifin JM, Chan SC (1995) Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic-dermatitis. J Invest Dermatol 105: S84–S88

    Article  Google Scholar 

  24. Chan SC, Kim JW, Henderson WR, Jr., Hanifin JM (1993) Altered prostaglandin E2 regulation of cytokine production in atopic dermatitis. J Immunol 151: 3345–3352

    PubMed  CAS  Google Scholar 

  25. Betz M, Fox BS (1991) Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 146: 108–113

    PubMed  CAS  Google Scholar 

  26. Safko MJ, Chan SC, Cooper KD, Hanifin JM (1981) Heterologous desensitisation of leukocytes: a possible mechanism for beta adrenergic blockade in atopic dermatitis. J Allergy Clin Immunol 68: 218–225

    Article  PubMed  CAS  Google Scholar 

  27. Grewe SR, Chan SC, Hanifin JM (1982) Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness. J Allergy Clin Immunol 70: 452–457

    Article  PubMed  CAS  Google Scholar 

  28. Sawai T, Ikai K, Uehara M (1998) Cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leucocytes from patients with atopic dermatitis: correlation with respiratory atopy. Br J Dermatol 138: 846–848

    Article  PubMed  CAS  Google Scholar 

  29. Heskel NS, Chan SC, Thiel ML, Stevens SR, Casperson LS, Hanifin JM (1984) Elevated umbilical-cord blood leukocyte cyclic adenosine-monophosphate phosphodiesterase activity in children with atopic parents. J Am Acad Dermatol 11: 422–426

    Article  PubMed  CAS  Google Scholar 

  30. Mcmillan JC, Heskel NS, Hanifin JM (1985) Cyclic AMP-phosphodiesterase activity and histamine-release in cord blood leukocyte preparations. Acta Dermato-Venereologica 5114: 24–32

    Google Scholar 

  31. Holden CA, Chan SC, Hanifin JM (1986) Monocyte localization of elevated cAMP phosphodiesterase activity in atopic dermatitis. J Invest Dermatol 87: 372–376

    Article  PubMed  CAS  Google Scholar 

  32. Chan SC, Reifsnyder D, Beavo JA, Hanifin JM (1993) Immunochemical characterization of the distinct monocyte cyclic amp-phosphodiesterase from patients with atopicdermatitis. J Allergy Clin Immunol 91: 1179–1188

    Article  PubMed  CAS  Google Scholar 

  33. Crocker IC, Ohia SE, Church MK, Townley RG (1998) Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors. J Allergy Clin Immunol 102: 797–804

    Article  PubMed  CAS  Google Scholar 

  34. Gantner F, Tenor H, Gekeler V, Schudt C, Wendel A, Hatzelmann A (1997) Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study. J Allergy Clin Immunol 100: 527–535

    Article  PubMed  CAS  Google Scholar 

  35. Li SH, Chan SC, Kramer SM, Hanifin JM (1993) Modulation of leukocyte cyclic AMP phosphodiesterase activity by recombinant interferon-gamma: evidence for a differential effect on atopic monocytes. J Interferon Res 13: 197–202

    Article  PubMed  Google Scholar 

  36. Spina D, Landells LJ, Page CP (1998) The role of theophylline and phosphodiesterase 4 isoenzyme inhibitors as anti-inflammatory drugs. Clin Exp Allergy 28: 24–34

    PubMed  CAS  Google Scholar 

  37. Cooper KD, Kang K, Chan SC, Hanifin JM (1985) Phosphodiesterase inhibition by Ro20–1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro. J Invest Dermatol 84: 477–482

    Article  PubMed  CAS  Google Scholar 

  38. Chan SC, Li SH, Hanifin JM (1993) Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphatephosphodiesterase activity and is reversible by phosphodiesterase inhibition. J Invest Dermatol 100: 681–684

    Article  PubMed  CAS  Google Scholar 

  39. Tenor H, Hatzelmann A, Church MK, Schudt C, Shute JK (1996) Effects of theophylline and rolipram on leukotriene C-4 (LTC(4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Brit J Pharmacol 118: 1727–1735

    Article  CAS  Google Scholar 

  40. Lidington E, Nohammer C, Dominguez M, Ferry B, Rose ML (1996) Inhibition of the transendothelial migration of human lymphocytes but not monocytes by phosphodiesterase inhibitors. Clin Exp Immunol 104: 66–71

    Article  PubMed  CAS  Google Scholar 

  41. Essayan DM, Huang SK, Kageysobotka A, Lichtenstein LM (1995) Effects of nonselective and isozyme-selective cyclic-nucleotide phosphodiesterase inhibitors on antigen-induced cytokine gene-expression in peripheral-blood mononuclear-cells. Am J Resp Cell Mol Biol 13: 692–702

    CAS  Google Scholar 

  42. Banner KH, Page CP (1995) Theophylline and selective phosphodiesterase inhibitors as antiinflammatory drugs in the treatment of bronchial-asthma. Eur Resp J 8: 996–1000

    CAS  Google Scholar 

  43. Massey WA (1993) Pathogenesis and pharmacological modulation of the cutaneous late-phase reaction. Ann Allergy 71: 578–584

    PubMed  CAS  Google Scholar 

  44. Talbot SF, Atkins PC, Goetzl EJ, Zweiman B (1985) Accumulation of leukotriene C4 and histamine in human allergic skin reactions. J Clin Invest 76: 650–656

    Article  PubMed  CAS  Google Scholar 

  45. Fauler J, Neumann C, Tsikas D, Frolich JC (1993) Enhanced synthesis of cysteinyl leukotrienes in atopic-dermatitis. Br J Dermatol 128: 627–630

    Article  PubMed  CAS  Google Scholar 

  46. Sansom JE, Taylor GW, Dollery CT, Archer CB (1997) Urinary leukotriene E-4 levels in patients with atopic dermatitis. Br J Dermatol 136: 790–791

    Article  PubMed  CAS  Google Scholar 

  47. Carucci JA, Washenik K, Weinstein A, Shupack J, Cohen DE (1998) The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch Dermatol 134: 785–786

    Article  PubMed  CAS  Google Scholar 

  48. Parrish JA, Jaenicke KF (1981) Action spectrum for phototherapy of psoriasis. J Invest Dermatol 76(5): 359–362

    Article  PubMed  CAS  Google Scholar 

  49. Jekler J, Larko O (1988) UVB phototherapy of atopic dermatitis. Br J Dermatol 119 (6): 697–705

    Article  PubMed  CAS  Google Scholar 

  50. Jekler J, Larko O (1990) Combined UVA-UVB versus UVB phototherapy for atopic dermatitis: A paired comparison study. J Am Acad Dermatol 22: 49–53

    Article  PubMed  CAS  Google Scholar 

  51. Wulf HC, Bech Thomsen N (1998) A UVB phototherapy protocol with very low dose increments as a treatment of atopic dermatitis. Photodermatol Photoimmunol Photomed 14 (1): 1–6

    Article  PubMed  CAS  Google Scholar 

  52. Midelfart K, Stenvold SE, Volden G (1985) Combined UVB and UVA phototherapy of atopic eczema. Dermatologica 171 (2): 95–98

    Article  PubMed  CAS  Google Scholar 

  53. George SA, Bilsland DJ, Johnson BE, Ferguson J (1993) Narrow-band (TL-01) UVB air-conditioned phototherapy for chronic severe adult atopic dermatitis. Br J Dermatol 128: 49–56

    Article  PubMed  CAS  Google Scholar 

  54. Collins P, Ferguson J (1995) Narrowband (TL-01) UVB air-conditioned phototherapy for atopic eczema in children. Br J Dermatol 133 (4): 653–655

    Article  PubMed  CAS  Google Scholar 

  55. Krutmann J, Czech W, Diepgen T, Niedner R, Kapp A, Schopf E (1992) High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol 26: 225–230

    Article  PubMed  CAS  Google Scholar 

  56. Grabbe J, Welker P, Humke S, Grewe M, Schopf E, Henz BM, Krutmann J (1996) High-dose ultraviolet Al (UVA1), but not UVA/UVB therapy, decreases IgE-binding cells in lesional skin of patients with atopic eczema. J Invest Dermatol 107 (3): 419–422

    Article  PubMed  CAS  Google Scholar 

  57. Krutmann J, Diepgen TL, Luger TA, Grabbe S, Meffert H, Sonnichsen N, Czech W, Kapp A, Stege H, Grewe M et al (1998) High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. J Am Acad Dermatol 38 (4): 589–593

    Article  PubMed  CAS  Google Scholar 

  58. Morison WL, Parrish J, Fitzpatrick TB (1978) Oralen psoralen photochemotherapy of atopic eczema. Br J Dermatol 98 (1): 25–30

    Article  PubMed  CAS  Google Scholar 

  59. Yoshiike T, Aikawa Y, Sindhvananda J, Ogawa H (1993) A proposed guideline for psoralen photochemotherapy (PUVA) with atopic dermatitis: successful therapeutic effect on severe and intractable cases. J Dermatol Sci 5: 50–53

    Article  PubMed  CAS  Google Scholar 

  60. Atherton DJ, Carabott F, Glover MT, Hawk JL (1988) The role of psoralen photochemotherapy (PUVA) in the treatment of severe atopic eczema in adolescents. Br J Dermatol 118 (6): 791–795

    Article  PubMed  CAS  Google Scholar 

  61. Sheehan MP, Atherton DJ, Norris P, Hawk J (1993) Oral psoralen photochemotherapy in severe childhood atopic eczema: an update. Br J Dermatol 129: 431–436

    Article  PubMed  CAS  Google Scholar 

  62. Lindelof B, Sigurgeirsson B, Tegner E, Larko O, Johannesson A, Berne B, Christensen OB, Andersson T, Torngren M, Molin L et al (1991) PUVA and cancer: a large-scale epidemiological study. Lancet 338 (8759): 91–93

    Article  PubMed  CAS  Google Scholar 

  63. Kaidbey KH, Kligman AM (1981) Cumulative effects from repeated exposures to ultraviolet radiation. J Invest Dermatol 76 (5): 352–355

    Article  PubMed  CAS  Google Scholar 

  64. Parrish JA, Zaynoun S, Anderson RR (1981) Cumulative effects of repeated subthreshold doses of ultraviolet radiation. J Invest Dermatol 76 (5): 356–358

    Article  PubMed  CAS  Google Scholar 

  65. Storbeck K, Holzle E, Schurer N, Lehmann P, Plewig G (1993) Narrow-band UVB (311 nm) versus conventional broad-band UVB with and without dithranol in phototherapy for psoriasis. J Am Acad Dermatol 28 (2 Pt 1): 227–231

    Article  PubMed  CAS  Google Scholar 

  66. van Iperen HP, Beijersbergen van Henegouwen GMJ (1997) Clinical and mechanistic aspects of photopheresis. J Photochem Photobiol B-Biology 93: 99–109

    Article  Google Scholar 

  67. Richter HI, Billmann Eberwein C, Grewe M, Stege H, Berneburg M, Ruzicka T, Krutmann J (1998) Successful monotherapy of severe and intractable atopic dermatitis by photopheresis. J Am Acad Dermatol 38(4): 585–588

    Article  PubMed  CAS  Google Scholar 

  68. Sheehan MP, Rustin MH, Atherton DJ, Buckley C, Harris DW, Brostoff J, Ostlere L, Dawson A, Harris DJH (1992) Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis. Lancet 340: 13–17

    Article  PubMed  CAS  Google Scholar 

  69. Latchman Y, Bannerjee P, Poulter LW, Rustin MH, Brostoff J (1996) Association of immunological changes with clinical efficacy in atopic eczema patients treated with traditional Chinese herbal therapy (Zemaphyte). Int Arch Allergy Immunol 109: 243–249

    Article  PubMed  CAS  Google Scholar 

  70. Latchman Y, Whittle B, Rustin MH, Atherton DJ, Brostoff J (1994) The efficacy of traditional Chinese herbal therapy in atopic eczema. Int Arch Allergy Immunol 104 (3): 222–226

    Article  PubMed  CAS  Google Scholar 

  71. Latchman Y, Bungy GA, Atherton DJ, Rustin MH, Brostoff J (1995) Efficacy of traditional Chinese herbal therapy in vitro. A model system for atopic eczema: inhibition of CD23 expression on blood monocytes. Br J Dermatol 132 (4): 592–598

    Article  PubMed  CAS  Google Scholar 

  72. Xu XJ, Banerjee P, Rustin MH, Poulter LW (1997) Modulation by Chinese herbal therapy of immune mechanisms in the skin of patients with atopic eczema. Br J Dermatol 136 (1): 54–59

    Article  PubMed  CAS  Google Scholar 

  73. Sheehan MP, Atherton DJ (1992) A controlled trial of traditional Chinese medicinal plants in widespread non-exudative atopic eczema. Br J Dermatol 126: 179–184

    Article  PubMed  CAS  Google Scholar 

  74. Sheehan MP, Stevens H, Ostlere LS, Atherton DJ, Brostoff J, Rustin MH (1995) Follow-up of adult patients with atopic eczema treated with Chinese herbal therapy for 1 year. Clin Exp Dermatol 20 (2): 136–140

    Article  PubMed  CAS  Google Scholar 

  75. Sheehan MP, Atherton DJ (1994) One-year follow up of children treated with Chinese medicinal herbs for atopic eczema. Br J Dermatol 130: 488–493

    Article  PubMed  CAS  Google Scholar 

  76. Graham-Brown RAC (1992) Toxicity of Chinese herbal remedies. Lancet 340: 673

    Article  PubMed  CAS  Google Scholar 

  77. Perharic-Walton L, Murray V (1992) Liver failure after traditional Chinese herbal therapy. Lancet 340: 674

    Article  PubMed  CAS  Google Scholar 

  78. Perharic L, Shaw D, Leon C, De Smet PA, Murray VS (1995) Possible association of liver damage with the use of Chinese herbal medicine for skin disease. Vet Hum Toxicol 37: 562–566

    PubMed  CAS  Google Scholar 

  79. Ferguson JE, Chalmers RJ, Rowlands DJ (1997) Reversible dilated cardiomyopathy following treatment of atopic eczema with Chinese herbal medicine. Br J Dermatol 136 (4): 592–593

    Article  PubMed  CAS  Google Scholar 

  80. Souillet G, Rousset F, de Vries JE (1989) Alpha-interferon treatment of patient with hyper IgE syndrome [letter]. Lancet 1: 1384

    Article  PubMed  CAS  Google Scholar 

  81. Nielsen BW, Reimert CM, Hammer R, Schiotz PO, Thestrup Pedersen K (1994) Interferon therapy for atopic dermatitis reduces basophil histamine release, but does not reduce serum IgE or eosinophilic proteins. Allergy 49: 120–128

    Article  PubMed  CAS  Google Scholar 

  82. Gruschwitz MS, Peters KP, Heese A, Stosiek N, Koch HU, Hornstein OP (1993) Effects of interferon-alpha-2b on the clinical course, inflammatory skin infiltrates and peripheral blood lymphocytes in patients with severe atopic eczema. Int Arch Allergy Immunol 101: 20–30

    Article  PubMed  CAS  Google Scholar 

  83. Torrelo A, Harto A, Sendagorta E, Czarnetzki BM, Ledo A (1992) Interferon-alpha therapy in atopic dermatitis. Acta Derm Venereol (Stockh) 72: 370–372

    CAS  Google Scholar 

  84. Reinhold U, Kukel S, Brzoska J, Kreysel HW (1993) Systemic interferon gamma treatment in severe atopic dermatitis. J Am Acad Dermatol 29: 58–63

    Article  PubMed  CAS  Google Scholar 

  85. Hanifin JM, Schneider LC, Leung DYM, Ellis CN, Jaffe HS, Izu AE, Bucalo LR, Hirabayashi SE, Tofte SJ, Cantugonzales G, et al (1993) Recombinant interferon gamma-therapy for atopic-dermatitis. J Am Acad Dermatol 28: 189–197

    Article  PubMed  CAS  Google Scholar 

  86. Stevens SR, Hanifin JM, Hamilton T, Tofte SJ, Cooper KD (1998) Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 134: 799–804

    Article  PubMed  CAS  Google Scholar 

  87. Harper JI, Mason UA, White TR, Staughton RC, Hobbs JR (1991) A double-blind placebo-controlled study of thymostimulin (TP-1) for the treatment of atopic eczema. Br J Dermatol 125: 368–372

    Article  PubMed  CAS  Google Scholar 

  88. Hsieh KH, Shaio MF, Liao TN (1992) Thymopentin treatment in severe atopic dermatitis--clinical and immunological evaluations. Arch Dis Child 67: 1095–1102

    Article  PubMed  CAS  Google Scholar 

  89. Stiller MJ, Shupack JL, Kenny C, Jondreau L, Cohen DE, Soter NA (1994) A double-blind, placebo-controlled clinical-trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic-dermatitis. J Am Acad Dermatol 30: 597–602

    Article  PubMed  CAS  Google Scholar 

  90. Colloff MJ (1992) Exposure to house dust mite in homes of people with atopic dermatitis. Br J Dermatol 127: 322–327

    Article  PubMed  CAS  Google Scholar 

  91. Colloff MJ, Ayres J, Carswell F, Howarth PH, Merrett TG, Mitchell EB, Walshaw MJ, Warner JO, Warner JA, Woodcock AA (1992) The control of allergens of dust mites and domestic pets: a position paper. Clin Exp Allergy 22 (Supp 2): 1–28

    Article  PubMed  Google Scholar 

  92. Dorward AJ, Colloff MJ, Mackay NS, McSharry C, Thompson NC (1988) Effect of house dust mite avoidance measures in adult atopic asthma. Thorax 43: 98–102

    Article  PubMed  CAS  Google Scholar 

  93. Andersen A, Rosen J (1989) House dust mite Dermatophagoides pteronyssinus and its allergens: effects of washing. Allergy 44: 396–400

    Article  PubMed  CAS  Google Scholar 

  94. Morrow Brown H, Merrett TG (1991) Effectiveness of an acaricide in management of house dust mite allergy. Ann Allergy 67: 25–31

    Google Scholar 

  95. Mitchell EB, Wilkins S, McCallum Deighton J, Plaits-Mills TAE (1985) Reduction of house dust mite allergen levels in the home: use of the acaricide, pirimiphos methyl. Clin Allergy 15: 235–240

    Article  PubMed  CAS  Google Scholar 

  96. Cameron MM (1997) Can house dust mite-triggered atopic dermatitis be alleviated using acaricides? Br J Dermatol 137: 1–8

    Article  PubMed  CAS  Google Scholar 

  97. Weeks J, Oliver J, Birmingham K, Crewes A, Carswell F (1995) A combined approach to reduce mite allergen in the bedroom. Clin Exp Allergy 25: 1179–1183

    Article  PubMed  CAS  Google Scholar 

  98. Tan BB, Weald D, Strickland I, Friedmann PS (1996) Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet 347: 15–18

    Article  PubMed  CAS  Google Scholar 

  99. Green WF, Nicholas NR, Salome CM, Woolcock AJ (1989) Reduction of house dust mite and mite allergens: effects of spraying carpets and blankets with Allersearch DMS, an acaricide combined with an allergen reducing agent. Clin Exp Dermatol 19: 203–207

    CAS  Google Scholar 

  100. Warner JA, Marchant JL, Warner JO (1993) Allergen avoidance in the homes of asthmatic children: the effect of Allersearch DMS. Clin Exp Allergy 23: 279–286

    Article  PubMed  CAS  Google Scholar 

  101. Platts-Mills TAE, Mitchell EB, Rowntree S, Chapman MD, Wilkins SR (1983) The role of house dust mite allergens in atopic dermatitis. Clin Exp Dermatol 8: 233–247

    Article  PubMed  CAS  Google Scholar 

  102. Sanda T, Yasue T, Oohashi M, Yasue A (1992) Effectiveness of house dust-mite allergen avoidance through clean room therapy in patients with atopic dermatitis. J Allergy Clin Immunol 89: 653–657

    Article  PubMed  CAS  Google Scholar 

  103. Clark RA, Adinoff AD (1989) Aeroallergen contact can exacerbate atopic dermatitis: patch tests as a diagnostic tool. J Am Acad Dermatol 21: 863–869

    Article  PubMed  CAS  Google Scholar 

  104. Roberts DLL (1984) House dust mite avoidance and atopic dermatitis. Br J Dermatol 110: 735–736

    Article  PubMed  CAS  Google Scholar 

  105. August PJ (1984) House dust mite causes atopic eczema. A preliminary study. Br J Dermatol 111 (26): 10–11

    Article  Google Scholar 

  106. Denman AM, Cornthwaite D (1990) Control of house dust mite in bedding. Lancet 335: 1038

    Article  PubMed  CAS  Google Scholar 

  107. Marks GB, Tovey ER, Green W, Shearer M, Salome CM, Woolcock AJ (1994) House dust mite allergen avoidance: a randomised controlled trial of surface chemical treatment and encasement of bedding. Clin Exp Allergy 24: 1078–1083

    Article  CAS  Google Scholar 

  108. Kalra S, Crank P, Hepworth J, Pickering CAC, Woodcock AA (1993) Concentrations of domestic house dust mite allergen Der p1 after treatment with solidified benzyl benzoate (Acarosan) or liquid nitrogen. Thorax 48: 10–13

    Article  PubMed  CAS  Google Scholar 

  109. Murray AB, Ferguson AC (1983) Dust free bedrooms in the treatment of asthmatic children with house dust mite allergy: a controlled trial. Pediatrics 71: 418–422

    PubMed  CAS  Google Scholar 

  110. Walshaw MJ, Evans CC (1986) Allergen avoidance in house dust mite sensitive adult asthma. QJM 58: 199–215

    PubMed  CAS  Google Scholar 

  111. Ehnert B, Lau-Schadendorf S, Weber A, Buettner P, Schou C, Wahn U (1992) Reducing domestic exposure to house dust mite allergen reduces bronchial hyperreactivity in sensitive children with asthma. J Allergy Clin Immunol 90: 135–138

    Article  PubMed  CAS  Google Scholar 

  112. Friedmann PS, Tan BB, Musaba E, Strickland I (1995) Pathogenesis and management of atopic dermatitis. Clin Exp Allergy 25: 799–806

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dermatopharmacology Unit, Southampton General Hospital, Level F, South Block, Southampton, SO16 6YD, UK

    Birgit A. Pees & Peter S. Friedmann

Authors
  1. Birgit A. Pees
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter S. Friedmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Dermatology, University Hospital Utrecht, Heidelberglaan 100, Utrecht, CX, NL-3584, Netherlands

    C. A. F. M. Bruijnzeel-Koomen  & E. Knol  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Basel AG

About this chapter

Cite this chapter

Pees, B.A., Friedmann, P.S. (2000). Future developments in treatment of atopic dermatitis. In: Bruijnzeel-Koomen, C.A.F.M., Knol, E. (eds) Immunology and Drug Therapy of Allergic Skin Diseases. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8464-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8464-8_12

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9579-8

  • Online ISBN: 978-3-0348-8464-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation